BeStock  
Stocks › Biotechnology › ASND

Ascendis Pharma A/S ASND

US equityMarket cap rank #1027Biotechnology
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership106.0%-0.04 pts vs. prior quarter
Institutions holding421-2 vs. prior quarter
Insider trades (recent)6 buys / 4 sellsNet buying
Short interest4.56% of floatDays to cover 5.0 · as of 30 Oct 2026
Short-sale volume share15.4%5-day average of daily volume

Short-sale volume as % of daily volume

9%17%24%32%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$4.97M (12 inflow days, 8 outflow days).

Net flow by order size, last 20 sessions

−$9.4MSuper+$4.5MBig+$19.8MMid+$25.7MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 50.6% of shares outstanding.

Largest holders

  • RA Capital Management, L.P.15.67%
  • T. Rowe Price Group, Inc.13.89%
  • Westfield Capital Management Company, L.P.7.81%
  • Avoro Capital Advisors LLC7.70%
  • Janus Henderson Group plc5.57%
  • FMR5.25%
  • Wellington Management Group4.68%
  • Capital Research3.61%

By investor type

  • Mutual Fund71.27%
  • VC/PE Fund18.45%
  • Hedge Fund11.78%
  • Public Company2.29%
  • Private Company0.90%
  • Government Pension Fund0.51%
  • Sovereign Wealth Fund0.33%
  • Family Office/Trust0.17%

Reported short interest has fallen from 5.62% to 4.56% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Wellington Management Group Mutual Fund 2026/Q4 +1,521,763 4.7%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q4 +1,234,734 13.9%
Vestal Point Capital, LP Hedge Fund 2026/Q4 +365,000 1.1%
Chevy Chase Trust Company Mutual Fund 2026/Q4 +361,364 0.6%
Westfield Capital Management Company, L.P. Mutual Fund 2026/Q4 +326,760 7.8%
Principal Global Investors, LLC Mutual Fund 2026/Q4 +292,728 1.8%
Macquarie Investment Management Business Trust Mutual Fund 2026/Q4 +265,839 0.9%
Artal Group S.A. VC/PE Fund 2026/Q4 +130,000 0.2%
OrbiMed Advisors LLC VC/PE Fund 2026/Q4 +100,744 0.5%
BNY Mellon Asset Management Mutual Fund 2026/Q4 +97,759 0.6%
Arrowstreet Capital, Limited Partnership Mutual Fund 2026/Q4 +95,335 0.3%
Bank of America Corporation Public Company 2026/Q4 +83,068 0.4%
State Street Global Advisors Mutual Fund 2026/Q4 +76,251 0.9%
California Public Employees' Retirement System Government Pension Fund 2026/Q4 +74,449 0.1%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q4 +74,317 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
7 Sep 2026 Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer Derivative Exercise and Sale -3,000 $270.19 –
1 Sep 2026 Lars Holtug Independent Director Open Market Disposition -236 $264.13 4,000
13 Aug 2026 Jean-Jacques Bienaime Non-Executive Director Open Market Acquisition +2,000 $246.91 2,900
1 Jun 2026 Scott Smith CFO, Executive VP & Member of Executive Board Open Market Acquisition +100 $219.00 4,367
28 May 2026 Jean-Jacques Bienaime Non-Executive Director Open Market Acquisition +500 $223.76 900
28 May 2026 Scott Smith CFO, Executive VP & Member of Executive Board Open Market Acquisition +250 $223.32 4,267
25 May 2026 Jean-Jacques Bienaime Non-Executive Director Open Market Acquisition +400 $239.37 400
10 May 2026 Flemming Jensen Executive Vice President of Product Supply & Quality Open Market Disposition -19,460 $238.49 –
13 Apr 2026 Jean-Jacques Bienaime Non-Executive Director Derivative Sale to Issuer -9,160 – –
13 Apr 2026 Jean-Jacques Bienaime Non-Executive Director Other Derivative Acquisition +9,160 $249.84 9,160
22 Mar 2026 Jean-Jacques Bienaime Non-Executive Director Initial Statement of Beneficial +0 – 9,160
17 Mar 2026 Albert Cha Independent Chairperson Initial Statement of Beneficial +0 – 3,730
17 Mar 2026 Jan Mikkelsen President, CEO, Member of Executive Board & Executive Director Initial Statement of Beneficial +0 – 68,604
17 Mar 2026 Michael Jensen Executive VP, Chief Legal Officer & Member of the Executive Board Initial Statement of Beneficial +0 – 94,259
17 Mar 2026 Flemming Jensen Executive Vice President of Product Supply & Quality Initial Statement of Beneficial +0 – 19,460
17 Mar 2026 Pedersen Anni Lotte Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board Initial Statement of Beneficial +0 – 19,460
17 Mar 2026 Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer Initial Statement of Beneficial +0 – 36,804
17 Mar 2026 William Fairey Independent Director Initial Statement of Beneficial +0 – 2,117
17 Mar 2026 Lisa Morrison Independent Director Initial Statement of Beneficial +0 – 1,572
17 Mar 2026 Scott Smith CFO, Executive VP & Member of Executive Board Initial Statement of Beneficial +0 – 154,259

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 2,997,710 4.6% 5.0
15 Oct 2026 3,132,475 4.8% 4.2
30 Sep 2026 3,484,067 5.3% 3.7
15 Sep 2026 3,961,960 6.0% 4.9
31 Aug 2026 4,203,221 6.4% 9.5
14 Aug 2026 3,687,311 5.6% 6.3

Discussion

No comments yet — be the first to weigh in on ASND.

Sign in to join the discussion.

Scroll to Top